Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Research Abstract |
To improve the prognosis of cancer patients, it is essential to inhibit the capacity of cancer cells for hematogenous metastasis as well as their proliferative capacity. EG-VEGF factor enhances the angiogenesis and cell invasion in colon cancer. EG-VEGF antibody that we established, inhibibites the angiogenesis and cell inavasion in colon cancer. EG-VEGF molecule-targeted therapy has the potential for improving survival rates.
|